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Abstract 
Background 
Left ventricular assist device (LVAD) therapy has been thrust into the forefront of 
surgical treatment for advanced heart failure (HF).  Despite advancements in 
survival and quality of life with these devices, the multi-disciplinary care for these 
patients remains far from standardized across institutions. 
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Methods  
A survey of current practices in LVAD was carried out at the St. Jude Medical 
User’s meeting representing a variety of caregivers including cardiac surgeons, HF 
cardiologists, non-HF cardiologists, advanced practice providers and ventricular 
assist device coordinators, with representation from several continents.  Utilizing 
an audience response system, eleven questions were asked related to the 
demographics of the audience, left ventricular assist device patient selection and 
patient management. 
Results 
A total of 120 audience members representing both transplant and LVAD centers, 
destination therapy only LVAD centers and non-implanting, shared care centers 
across a multitude of disciplines responded to the survey.  Questions comprised of 
patient selection (body mass index, pre-existing renal failure, care giver presence 
and abstinence from substance abuse) and patient management (anticoagulation 
regimens, first line therapy for hemolysis, implantable cardioverter-defibrillator 
usage and route of preferred dialysis) issues. 
Conclusions 
LVAD technology will continue to change and improve with the next generation of  
pumps on the horizon.  Progress cannot be made without pausing to understand 
the current state of technology, practice patterns and patient determinants of 
success.  This survey underscores the lack of consensus regarding best practice 
principles and the need for an increased focus on care management for LVAD 
patients with collaborative, multi-institutional studies.  
Keywords:  Left ventricular assist device, mechanical circulatory support, heart 
failure 
Background 
There are an estimated 5.7 million people suffering from HF in the United States 
with 50% dying within five years of their diagnosis [1].  Although medical therapy 
and cardiac resynchronization therapy have made significant strides in the last two 
decades, they are still relatively futile in those with advanced stages of HF [2,3].  
Heart transplantation remains the gold standard of therapy for these patients; 
however, the increase in number of patients with HF combined with the limited 
donor organ availability have thrust left ventricular assist device (LVAD) therapy 
into the forefront of treatment.  Indeed, there are over 15,000 mechanical 
circulatory support devices that have been recorded in the INTERMACS 
(Interagency Registry for Mechanically Assisted Circulatory Support) registry alone 
since 2006, with annual LVAD implantations surpassing heart transplantation for 
the first time in 2014 [4]. 
Although LVAD therapy has become increasingly more popular with over 150 
implanting centers, the multi-disciplinary care for these patients remains far from 
standardized across institutions.  EMERG  (Evolving Mechanical Support 
Research Group) is a collaborative network of 17 physicians from high-volume  
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LVAD implanting centers, with a combination of cardiologists and cardiac surgeons 
focused on optimizing and standardizing care for the LVAD patient, and ultimately 
on conducting investigator-initiated, prospective, randomized, multi-center trials in 
patients with mechanical circulatory support.  We believe as members of EMERG, 
like HF care providers in every discipline, that we share a common passion for 
LVAD technology, because of the ever-invigorating fascination of rescuing patients 
from imminent death.  However, it is clear that significant controversies and 
differences in care practices exist amongst all institutions.  As clinicians caring for 
LVAD recipients, we frequently face clinical dilemmas without available data to 
provide guidance regarding best practices.  To glean insight into key topics where 
there are clear practice pattern variations across centers, we conducted a survey 
of the audience at the St. Jude Medical-sponsored User’s meeting in 2016.  In this 
manuscript, we summarize those findings with accompanying reviews on each 
topic. 
 
Methods 
The St. Jude Medical (LVAD) User’s meeting took place in Phoenix, Arizona in 
May 2016 and included a variety of caregivers including cardiac surgeons, heart 
failure cardiologists, non-heart failure cardiologists, advanced practice providers 
and ventricular assist device coordinators, with representation from several 
continents.  The survey concept and questions were conceived independently by 
members of EMERG, without any industry involvement or influence.  The User’s 
meeting was chosen intentionally by the EMERG investigators as the best avenue 
to conduct a survey that would be a true cross section of “best”, or at least most 
common, clinical practices, with substantial minimization of selection and 
participation bias given most traditional survey studies utilizing e-mail or U.S. mail 
as media have a shamefully poor response rate of less than 20% introducing 
irreconcilable skewing of survey results.  In contrast, as observed by the EMERG 
investigators, every institution which implants, or is planning to implant, LVADs, is 
invited to send representative members to the “User’s Meeting” with an attendance 
of 468 invited guests of which 218 were from an implanting center.  As such, the 
percentage of practicing LVAD implanting institutions included in this survey 
response should be substantially greater than e-mail based survey based 
questionnaires. Furthermore, it should be made abundantly clear that there was no 
contribution to any of the survey questions, or any part of any question, by any 
employee or functioning employee of St. Jude Medical.   Using an audience 
response system, eleven questions were asked related to the demographics of the 
audience, left ventricular assist device patient selection and patient management. 
Results  
The demographics-related questions in the survey were: 
Demographics:  Which of the below best describes your center?    
          a.   Transplant and LVAD center 
          b.    DT LVAD center 
          c.    Non-implanting, shared care site 
            d.    Neither 
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Demographics:  Which of the best describes your role? 
 
       a.     Surgeon 
       b.      HF Cardiologist 
       c.      Non HF cardiologist 
       d.      Advanced Practice Provider 
       e.      Coordinator 
       f.       Other 
 
There were a total of 120 respondents with 75.9% representing both a transplant 
and LVAD center, 18.3 % representing a destination therapy (DT) only LVAD 
center, 5.0 % representing a non-implanting, shared care center and 0.8 % 
representing none of these.  The audience was comprised of multiple disciplines 
(Figure 1). 
 
 
Figure 1:  Demographics of Survey Respondents  
The make-up of the respondents to the survey included a multitude of different 
backgrounds with heart failure (HF) cardiologists making up the largest number 
with 35.8% followed by heart failure cardiac surgeons at 30.0 % (n=120). 
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Questions regarding patient characteristics included: 
Is there a body mass index (BMI - kg/m2) above which your center would not 
offer an LVAD? 
 
 a.   > 40 kg/m2 
 b.   > 45 
 c.   > 50 
 d.   No limit  
 
Does your center implant LVAD in patients with end stage renal failure on 
chronic hemodialysis (excluding bridge to heart-kidney transplant)? 
 
 a.   yes 
 b.   no  
 
If your patient needs dialysis, what is your preferred route of dialysis? 
 a.   Tunneled central venous catheter  
 b.    Arterio-venous (AV) fistula 
 c.    AV graft  
 d.    Peritoneal dialysis  
 
The body mass index (BMI in kg/m2) above which a program would not offer LVAD 
implantation was > 40 in 23.8%, > 45 in 15.8%, > 50 in 16.8% and no limit in 
43.6% of respondents (n=101) (Table 1).  In patients with pre-existing end stage 
renal failure requiring chronic hemodialysis (excluding bridge to heart-kidney 
transplant candidates), nearly 90% responded that they would not offer LVAD 
therapy (n=104).  In patients requiring post-LVAD dialysis, the preferred route of 
dialysis was a tunneled central venous catheter in 48.4 %, an arterio-venous (AV) 
fistula in 33.0 %, peritoneal dialysis in 12.1 % and AV graft in 6.6 % of respondents 
(Table 2) (n=91).   
 
Table 1:  Body Mass Index above which one would not offer LVAD therapy  
Body mass index Respondents Count (%) 
> 40 (BMI) in kg/m2 24  (23.8) 
> 45 (BMI) in kg/m2 16  (15.8) 
> 50 (BMI) in kg/m2 17  (16.8) 
No limit 44  (43.6) 
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Table 2:  Preferred route of renal replacement therapy in patients requiring 
dialysis post-LVAD implantation 
Route of Dialysis Respondents Count (%) 
Tunneled central venous catheter 
44 (48.4) 
Arterio-venous (AV) fistula 
30 (33.0) 
AV graft 
6 (6.6) 
Peritoneal dialysis 
11 (12.1) 
 
Questions regarding psychosocial support and substance abuse included: 
Does your center mandate that LVAD candidates have 24 hour caregiver 
support?  
a. Yes – indefinitely  
b. Yes - for the first 3 months     
c. Yes - for the first 30 days         
d. Yes – but not 24 hours-a-day 
e. No   
 
For patients implanted as DT (destination therapy) – what is your stance on 
tobacco and THC (marijuana) use in your program? 
  
 a.   Require abstinence from THC, but not tobacco 
             b.   Require abstinence from tobacco, but not THC 
             c.   Require abstinence from BOTH tobacco and THC 
             d.   Do not require abstinence from either tobacco or THC 
             e.   Have a don’t ask/don’t tell policy  
 
As it relates to social requirements for LVAD therapy consideration, 10.7% of 
survey participants stated that they do not have a 24 hour caregiver support 
requirement, while the remaining respondents had variable requirements ranging 
from one month to indefinitely (n=103).  In patients implanted as destination 
therapy, there was an approximately even split between those who required 
abstinence from both tetrahydrocannabinol  (THC - marijuana) and tobacco 
(smoking) in 42.4 % to those who did not require abstinence from either tobacco or 
THC in 38.4 % of the audience (Table 3) (n=99). 
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Table 3:  Social requirements for LVAD consideration  
Social Requirement Question Respondents Count (%) 
1.  Does your center mandate that LVAD 
candidates have 24 hour caregiver support?   
 
     Yes – indefinitely  15 (14.6) 
     Yes – for the first 3 months  24 (23.3) 
     Yes – for the first 30 days 28 (27.2) 
     Yes – but not 24 hours-a-day 25 (24.3) 
     No 11 (10.7) 
2.  For patients implanted as destination therapy – 
what is your stance on tobacco and THC 
(marijuana) use in your program? 
 
    Require abstinence from THC, but not tobacco 11 (11.1) 
    Require abstinence from tobacco, but not THC 2 (2.0) 
    Require abstinence from BOTH tobacco and THC 42 (42.4) 
    Do not require abstinence from either  38 (38.4) 
    Have a don’t ask / don’t tell policy  6 (6.1) 
 
Questions regarding anticoagulation centered around: 
What laboratory test does your program use to monitor the intensity of  
intravenous heparin in patients with LVAD? 
 
 a.   aPTT (activated partial thromboplastin time) 
 b.   Anti-factor Xa 
 c.   ACT (activated clotting time) 
 d.   Do not use heparin 
 
In the asymptomatic, outpatient setting, your program’s approach for 
patients with a sub-therapeutic INR (international normalization ratio) is: 
a. Admit for heparin gtt bridge if INR < 2.0 
b. Admit for heparin if INR < 1.8 
c. Admit for heparin gtt bridge if INR < 1.5 
d. Use enoxaparin subcutaneous as outpatient bridge  
e. Observation as outpatient with increased Coumadin dosing 
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Most respondents reported using intravenous unfractionated heparin therapy post-
LVAD implantation (96.0 %), with 67.3 % reported utilizing activated partial 
thromboplastin time (aPTT) to monitor the effectiveness of their anticoagulation 
strategy (n=101).  Once patients were successfully transitioned to outpatient 
anticoagulation, there were clear differences in the management of patients with a 
sub-therapeutic INR (international normalization ratio).  In an asymptomatic, 
outpatient setting, 52.2 % of respondents stated they use enoxaparin as a bridging 
strategy for patients, while 27.2 % would admit for intravenous heparin bridging for 
varying degrees of sub-therapeutic INR.  The remainder of respondents (20.7 %) 
increased the intensity of outpatient Coumadin therapy without bridging therapy 
(Table 4) (n=92).  
 
Table 4:  Anticoagulation monitoring and outpatient strategy  
 
Anticoagulation Related Question  Respondents Count (%) 
1.  What laboratory test does your program use to 
monitor intensity of intravenous heparin therapy 
in patients with LVAD?  
 
     aPTT (activated partial thromboplastin time)  68 (67.3) 
     Anti-Factor Xa 24 (23.8) 
     ACT (activated clotting time) 5 (5.0) 
     Do not use heparin 4 (4.0) 
2.  In the asymptomatic, outpatient setting, your 
program’s approach for patients with a sub-
therapeutic INR (International normalization ratio) 
is? 
 
    Admit for heparin gtt bridge if INR < 2.0  3 (3.3) 
    Admit for heparin if INR < 1.8  8 (8.7) 
    Admit for heparin gtt bridge if INR < 1.5 14 (15.2) 
    Use enoxaparin subcutaneous as outpatient bridge  48 (52.2) 
    Observation as outpatient with increased 
Coumadin  
19 (20.7) 
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Question regarding pump thrombosis management included: 
In the setting of hemolysis (lactate dehydrogenase (LDH) > 3 x upper limit of 
normal) with the HeartMate II LVAD, what is your first line management?  
a. Observation   
b. Trial of medical therapy (intensification of anticoagulant/antithrombic 
therapy – excluding lytics) 
a. Thrombolytic therapy 
b. Direct surgical LVAD exchange 
 
In patients with evidence of hemolysis, defined as a lactate dehydrogenase (LDH) 
greater than three times the upper limit of normal) with a HeartMate II (St. Jude 
Medical, Pleasanton, CA) LVAD, first line management was intensification of 
anticoagulation and/or anti-thrombotic (excluding lytic) therapy in 79.4 % of 
respondents, with other choices being observation (10.9 %), thrombolytic therapy 
(2.2 %) and direct surgical LVAD exchange (7.6 %) (Figure 2) (n=92).   
 
 
 
Figure 2:  First line management in the setting of hemolysis defined as an 
elevated lactate dehydrogenase level with the HeartMate II.  
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The most common first line therapy for setting of hemolysis defined as lactate 
dehydrogenase (LDH) greater than three times upper limit of normal with the 
HeartMate II was intensification of anticoagulation and/or anti-thrombotic (defined 
as medical therapy excluding lytic) therapy in 79.4 % of respondents with other 
choices being observation (10.9 %), thrombolytic therapy (2.2 %) and direct 
surgical LVAD exchange (7.6 %) (n=92).  
Question regarding the use of defibrillator policy on LVAD patients included: 
Which of the following best describes your center’s policy regarding the use 
of ICDs (implantable cardioverter-defibrillator) in LVAD patients? 
       a.   All patients must have an active ICD prior to discharge  
        b.   All BTT (bridge-to-transplant) patients must be discharged with an active   
                   ICD  
             c.   All DT (destination therapy) patient must be discharged with an active ICD 
             d.   All patients are discharged with an inactivated ICD (if one was present  
                   prior to LVAD implantation) 
             e.   Patients can choose whether or not to be discharged home with either an  
                   active or inactivated ICD 
 
Policies reported for implantable cardioverter-defibrillators (ICDs) in patients after 
LVAD therapy were also variable.  A requirement for all patients to have an active 
ICD prior to discharge was reported by 31.0 % of respondents, active ICD only in 
BTT (bridge-to-transplant) patients by 11.3 %, ICD only in DT patients by 9.9 %, 
and inactivation regardless of intent of therapy by 7.0 %.  The majority (40.9%) 
responded that all patients can choose whether or not to be discharged home with 
either an active or inactivated ICD (Table 5) (n=71). Details of the questions did 
not allow for capture of data regarding patient history of ventricular arrhythmias.  
 
Table 5:  Center policy regarding the use of implantable cardioverter-
defibrillator (ICD) in LVAD patients  
Policy on ICD Respondents Count (%) 
All patients must have an active ICD prior to discharge  22 (31) 
All BTT (bridge-to-transplant) patients must be 
discharged with an active ICD 
9 (11.3) 
All DT (destination therapy) patients must be 
discharged with an active ICD 
8 (9.9) 
All patients must be discharged with an inactive ICD (if 
one was present prior to LVAD implantation) 
5 (7.0) 
Patients can choose whether or not to be discharged 
home with either and active or inactivated ICD 
29 (40.9) 
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Discussion  
Although there is a significant amount of literature on the impact of variables such 
as  the INTERMACS profile, patient age and center volume with regards to 
outcomes, there is a paucity of data on other factors that may influence a 
successful LVAD implant.  The field of surgical therapy for heart failure, in 
particular mechanical circulatory support, is an ever changing landscape with new 
devices, new techniques and new management paradigms.  As a result, no 
definitive evidence exists in the selection and management of these patients.   
 
The influence that body mass index (BMI in kg/m2) plays on surgical outcomes 
remains unclear [5,6].  Although there are theoretical considerations for driveline 
infections, pump migration, pump thrombosis or post-implant right ventricular 
failure, there is no consistency in our current understanding or the available 
literature.  The results of the survey confirm the lack of consensus that a specific 
BMI should preclude consideration for LVAD therapy.   
 
Perhaps the most nebulous criteria for patient selection is in the arena of 
psychosocial risk factors.  While professional guidelines suggest that all 
candidates for MCS be screened for psychosocial function before device 
placement, there are no standardized or validated methods to assess psychosocial 
function.  There are no universal behavioral? contraindications for LVAD 
placement, particularly when the intended strategy is DT, and thus there remain 
large inconsistencies among institutional practices.  Typically, these evaluations 
are “extrapolated” from the heart transplant literature.  The viewpoint of how much 
support is needed to care for these devices is also a critical one.  Without data to 
support adverse events in the absence of a 24-hour caregiver, it would be 
disappointing for an isolated criterion to prevent the application of this technology 
in patients who would otherwise benefit from it.  It is encouraging that the shift 
seen in our survey has increasing flexibility with regard to a caregiver plan. 
    
Unlike the clarity of data with the heart transplant literature, studies aiming to 
stratify risk according to social support in LVAD candidates have been less than 
impressive. [7].  Standardized instruments used for assessing transplant 
candidates, like the Psychosocial Assessment of Candidates for Transplantation 
(PACT) or the Stanford Integrated Psychosocial Assessment for Transplant 
(SIPAT) have not been studied in VAD patients.  In one retrospective study testing 
the utility of the transplant evaluation rating scale (TERS) in VAD recipients, none 
of the objective endpoints showed significant difference based on psychosocial 
risk profile. [8].  While more research is needed, it is encouraging to see the survey 
respondents seemingly less “prescriptive” with regard to social support for LVAD 
therapy.  
 
Patients are often denied therapy to transplantation because of either THC or 
tobacco addiction.  There are many centers that extend these criteria for LVAD 
therapy while others use it as a social stress test to determine transplant eligibility 
after LVAD implantation.  Smoking is an addiction and a proven risk factor for 
increased mortality and morbidity [9].  Previously described perioperative  
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complications and decreased survival in heart transplant recipients in addition to 
the need for patients to show their “participation in the healing process” have 
denied surgical therapy for patients suffering from advanced heart failure who 
continue to smoke.  Most centers require at least three months of abstinence from 
smoking to be considered for heart transplantation [10-12].  As seen from our 
survey, nearly half of the centers require the same for VADs as destination 
therapy.  Given the extent of the surgery and the consequences of the 
perioperative complications, it is imperative to educate patients on the importance 
of abstinence.   
 
Pre-implant renal dysfunction (RD) remains a strong predictor of post-LVAD 
mortality, particularly in those patients who are on dialysis at the time of surgery 
where the mortality rate exceeds 30% at 3 months post implant [13,14].   It is not 
surprising that 90% of reporting centers do not offer LVADs to chronic dialysis 
patients ineligible for heart-kidney transplantation.  However it is often patients with 
the most severe pre-implant RD who have the potential to experience marked 
improvements in renal function with mechanical support, assuming the RD present 
is HF-induced [15,16].  Unfortunately, there is currently no definitive testing to 
either differentiate HF-induced RD from other irreversible etiologies or to predict 
post-LVAD reversibility of RD. The management of renal failure in this population 
is further complicated by the lack of consensus on the best mode of renal 
replacement therapy. The most commonly utilized modality is tunneled catheters; 
however, there is significant risk of bacteremia and potential subsequent pump 
infection with continued use [17]. Unfortunately, the continuous-flow environment 
may impair a less infectious option, specifically the arteriovenous (AV) fistula, from 
maturing [18].  Still, AV fistulas and grafts have been used successfully in the 
LVAD population while peritoneal dialysis (PD) is only utilized at a small 
percentage of LVAD centers [19]. The theoretical advantage for PD is the 
reduction of systemic bacteremia, less hemodynamic variability, ability for daily 
ultrafiltration, and  importantly, the in-home use.   
 
Although ICDs have proven morbidity and mortality benefit in heart failure patients 
with reduced ejection fraction, we are lacking universal recommendations for ICD 
implantation in patients receiving a CF-LVAD or those already implanted with a 
CF-LVAD who do not have a pre-existing ICD.  In the pulsatile flow era, a 
retrospective analysis has shown improved survival in LVAD patients who have 
ICDs as well as improved survival to cardiac transplantation [20], however, this 
has not been demonstrated with contemporary CF-LVADs. A retrospective single 
center study of 23 consecutive patients implanted with a HeartMate II LVAD 
demonstrated that sustained ventricular tachycardia or fibrillation occurred in 52% 
of the patients, with the majority of arrhythmias occurring within the first month of 
LVAD implantation [21]. A prospective single center study of 94 patients showed 
that an absence of pre-operative ventricular arrhythmia conferred a low risk of 
post-operative ventricular arrhythmia [22].  In their analysis, none of the patients 
discharged from the hospital following CF-LVAD implant without an ICD died 
during median follow up of 12.7±12.3 months [22].   
 
Financial interests in reducing the burden of rehospitalization in the heart failure 
population in addition to optimizing care that can be provided in the outpatient  
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setting has led to differing approaches in LVAD patients with a sub-therapeutic 
INR. In the absence of published data to guide decision-making, the decision of 
whether and how to “bridge” patients with sub-therapeutic anticoagulation is 
center- and even clinician-specific.  At the very least, our survey provides 
confidence that there is no “standard” approach, and that a center- or patient-
specific approach is defensible.  
 
Intravenous unfractionated heparin remains the most commonly used parenteral 
anticoagulant for patients requiring anticoagulation. Activated partial 
thromboplastin time (aPTT) has been the standard method at most centers, 
regardless of the indication for anticoagulation although Anti-factor Xa (anti-FXa) 
has been suggested as an alternative method to ascertain whether a particular 
dose of heparin is therapeutic [23]. The choice of assay to monitor anticoagulation 
is often institution-specific and there is insufficient data to declare either the “gold 
standard.” Recent publications have highlighted a high level of discordance 
between aPTT and anti-FXa in the CF-VAD population, suggesting careful 
interpretation of available information [24,25].  Although a prospective randomized 
trial on this question is unlikely to be performed, perhaps a comparison of the rates 
of thrombosis and hemorrhage between centers that utilize the two different 
strategies could help us learn how to optimize anticoagulation in this challenging 
population.  In this era of heightened awareness of pump thrombosis and its 
negative impact on survival, it would not be surprising to learn that circumstances 
may dictate the optimal strategy with perhaps differing anticoagulation protocols.  
  
Unfortunately, suspected device thrombosis continues to be a common clinical 
problem in the CF-LVAD population. The gold standard for known thrombosis 
would be device removal (either device exchange with replacement or 
transplantation), but efforts to treat medically have been advocated by some.  
Methods include GPIIbIIIa inhibitors and thrombolytics each with a significant risk 
of severe and/or catastrophic intracranial bleeding [25,26]. On the other hand,  
patients are often asymptomatic and reluctant to undergo device exchange, 
particularly if soon after their initial implant.  Medical comorbidities may also 
contribute to high (or prohibitive) risk of device replacement. In this context, it is 
not surprising that the results of our survey show an overwhelming first line usage 
of medical therapy.   
 
A promising alternative in reducing morbidity and mortality of pump exchange has 
been the advent of minimally invasive pump exchange through a subcostal 
approach [27].  Considering the limited success of medical therapy in achieving 
lasting resolution of pump thrombosis, more widespread application of minimally 
invasive pump exchange could improve overall outcome of patients affected by 
pump thrombosis and make this more mainstream. However, it is noteworthy that 
the minimally invasive technique cannot be applied to situations where pump 
thrombosis occurs in association with inflow cannula malposition - which is the 
most commonly seen scenario in late (>1 year) presentation. Although it might be 
tempting to persevere with medical therapy in these cases to avoid a high risk 
exchange operation, it is ironic that these are often the cases which respond the 
least to non-surgical approaches because of the anatomical substrate responsible 
for pump thrombosis.   
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Conclusions 
 
It is only through honest dialogue regarding our collective experiences in the 
mechanical support community that we can hope to have more fruitful discussions 
with our patients and ourselves regarding best care practices. While some 
complications are indeed rare, difficult clinical scenarios are unfortunately too 
common. The dissemination of information amongst all centers will help clinicians 
discuss not only the current trends in practice but will enable the clinician to have a 
more insightful conversation with alternatives and indications with their patients of 
a specified therapy. LVAD technology will continue to change and improve with the 
next set of pumps on the horizon.  Undoubtedly, the current state of LVADs is for 
better access for patients to these devices with less adverse events. These will be 
coupled with the search for better hemocompatibility, smaller devices with less 
surgical morbidity, longer battery life, more user friendly controllers and 
transcutaneous power. Progress in these fields cannot be made independently 
without pausing to understand the current state of technology, practice patterns 
and patient determinants of success with LVAD therapy.  It is no longer enough to 
merely have better machines for better results.  This survey underscores the lack 
of consensus regarding best practice principles.  A great deal of time, energy and 
resources are invested in looking in the future to the next, new device without a 
clear understanding of optimal care practices after implant.  The LVAD guidelines 
are dominated by “level of evidence C” recommendations, with most extrapolated 
from single institutional studies [28]. There needs to be an increased focus on care 
management for LVAD patients with collaborative, multi-institutional studies.  We 
must hold each other accountable for getting away from institutional dogma and 
have more cross talk to get better results for our complex patients suffering from 
advanced heart failure. 
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